bluebird bio, Inc. (NASDAQ:BLUE) Receives $44.60 Consensus PT from Analysts

bluebird bio, Inc. (NASDAQ:BLUE) has received a consensus recommendation of “Hold” from the eight brokerages that are presently covering the firm, MarketBeat reports. Six research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $44.60.

BLUE has been the subject of a number of research analyst reports. Wall Street Zen started coverage on shares of bluebird bio in a report on Thursday, May 15th. They issued a “sell” rating for the company. Wells Fargo & Company cut their target price on shares of bluebird bio from $40.00 to $5.00 and set an “equal weight” rating for the company in a research note on Monday, February 24th. Barclays decreased their price target on shares of bluebird bio from $40.00 to $8.00 and set an “overweight” rating on the stock in a research report on Monday, March 31st. Baird R W downgraded bluebird bio from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 21st. Finally, JPMorgan Chase & Co. raised bluebird bio from an “underweight” rating to a “neutral” rating in a research note on Monday, February 24th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of BLUE. Regeneron Pharmaceuticals Inc. acquired a new stake in bluebird bio during the 4th quarter worth about $175,000. Goldman Sachs Group Inc. lifted its position in bluebird bio by 4.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 64,950 shares of the biotechnology company’s stock worth $317,000 after buying an additional 2,932 shares in the last quarter. Murchinson Ltd. acquired a new stake in shares of bluebird bio during the 1st quarter valued at $254,000. Groupe la Francaise purchased a new position in shares of bluebird bio during the 1st quarter valued at $679,000. Finally, Bank of New York Mellon Corp increased its stake in shares of bluebird bio by 12.7% in the first quarter. Bank of New York Mellon Corp now owns 32,759 shares of the biotechnology company’s stock worth $160,000 after acquiring an additional 3,686 shares during the last quarter. Hedge funds and other institutional investors own 87.43% of the company’s stock.

bluebird bio Price Performance

bluebird bio stock opened at $4.97 on Wednesday. bluebird bio has a 52 week low of $3.20 and a 52 week high of $28.60. The stock has a market cap of $48.67 million, a price-to-earnings ratio of -0.13 and a beta of 0.27. The company’s 50-day moving average price is $4.54 and its two-hundred day moving average price is $5.91. The company has a current ratio of 0.51, a quick ratio of 0.33 and a debt-to-equity ratio of 0.37.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.